Related Experiment Video
Updated: Jun 8, 2026
07:18
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
Histiocytic sarcoma with two immunohistopathologically distinct populations.
Kanako Wakahashi1, Manabu Shimoyama, Yoshio Katayama
1Hematology, Department of Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
International Journal of Hematology
|October 7, 2010
Summary
Histiocytic sarcoma (HS) can present with two distinct cell populations. CD163+ cells indicate resistance to chemo-radiotherapy, suggesting a potential marker for treatment outcomes in HS.
Area of Science:
- Oncology
- Immunohistopathology
- Cancer Biology
Background:
- Histiocytic sarcoma (HS) is a rare and aggressive malignancy.
- Understanding the heterogeneity of HS is crucial for effective treatment strategies.
Observation:
- This case report details a histiocytic sarcoma with two immunohistopathologically distinct tumor cell populations.
- Population A: Oval, CD68+, lysozyme+, CD163- cells.
- Population B: Spindle-shaped, CD68+, lysozyme-, CD163+ cells.
Findings:
- Cervical lymph node metastasis was predominantly Population A, responding well to chemotherapy.
- Hilar lymph node metastasis was mainly Population B, showing resistance to chemo-radiotherapy.
- CD163 expression was associated with chemo-radiotherapy resistance in HS.
Implications:
- CD163 may serve as a predictive biomarker for chemo-radiotherapy resistance in histiocytic sarcoma.
- The existence of CD163-negative HS suggests potential therapeutic sensitivity in certain stages.
- Further research into distinct HS cell populations could refine prognostic and therapeutic approaches.
